• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Freudenthaler Paul D

    3/4/26 4:20:17 PM ET
    $BMGL
    Medical/Nursing Services
    Health Care
    Get the next $BMGL alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    FREUDENTHALER PAUL D

    (Last) (First) (Middle)
    6 NAPIER ROAD,
    UNIT #02-10/11 GLENEAGLES MEDICAL CENTRE

    (Street)
    SINGAPORE 258499

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/18/2025
    3. Issuer Name and Ticker or Trading Symbol
    Basel Medical Group Ltd [ BMGL ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Paul Freudenthaler 03/04/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BMGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMGL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Freudenthaler Paul D

    3 - Basel Medical Group Ltd (0002004489) (Issuer)

    3/4/26 4:20:17 PM ET
    $BMGL
    Medical/Nursing Services
    Health Care

    $BMGL
    SEC Filings

    View All

    SEC Form 6-K filed by Basel Medical Group Ltd

    6-K - Basel Medical Group Ltd (0002004489) (Filer)

    1/23/26 4:30:24 PM ET
    $BMGL
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by Basel Medical Group Ltd

    6-K - Basel Medical Group Ltd (0002004489) (Filer)

    1/21/26 8:20:10 AM ET
    $BMGL
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by Basel Medical Group Ltd

    6-K - Basel Medical Group Ltd (0002004489) (Filer)

    12/1/25 5:00:26 PM ET
    $BMGL
    Medical/Nursing Services
    Health Care

    $BMGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Receipt of Delinquency Notification from Nasdaq

    Singapore, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that it has received notification from Nasdaq that based on the closing bid price of the Company's shares for the last 30 consecutive business days, the Company no longer meets the requirements under Nasdaq's Listing Rules (the "Rules") for listed securities to maintain a minimum bid price of $1 per share. The Rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company's security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provid

    1/23/26 4:30:00 PM ET
    $BMGL
    Medical/Nursing Services
    Health Care

    Receipt of Delinquency Notification from Nasdaq

    Singapore, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that it has received notification from Nasdaq that the Company's annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company's auditor, NLA DFK Assurance PAC, on the Company's financial statements. Pursuant to Listing Rule 5250(c)(1), companies shall timely file all required periodic financial reports with the United States Securities and Exchange Commission, and annual reports filed shall contain audited financial stat

    12/1/25 4:30:00 PM ET
    $BMGL
    Medical/Nursing Services
    Health Care

    Basel Medical Group Putting On Hold On The Acquisition of BTC Digital Asset

    Singapore, July 17, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced that it is putting on hold on the acquisition of BTC digital asset. After thorough discussions, Basel and the consortium of Bitcoin (BTC) holders have mutually agreed to pause the acquisition of digital asset. This decision reflects the ongoing regulatory review of digital assets by US authorities and the current lack of clarity on how forthcoming policies may impact the transaction. Given these uncertainties, both parties believe it is prudent to defer the deal until there is greater regulatory certainty. We will continue to monitor developments closely and reassess the opportunity once th

    7/17/25 4:30:00 PM ET
    $BMGL
    Medical/Nursing Services
    Health Care